Topics:
Breast Cancer • Medical Oncology • Journal Club ft. NEJM publications • Breast Cancer, Metastatic • HER2-low
What is trastuzumab deruxtecan's activity for patients with CNS+ disease?
Is there evidence that T-DXd crosses the blood-brain barrier?
Answer from: Medical Oncologist at Academic Institution
The DESTINY-Breast04 trial excluded patients with active CNS metastases so the study does not provide information on the activity of this drug in HER2-low CNS disease. In HER2-positive disease, however, CNS activity has been observed with trastuzumab deruxtecan; among patients evaluated for CNS resp...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In HER2 amplified patients with stable brain metastasis, T-DXd was associated with similar PFS compared to those without brain metastasis in the DESTINY-Breast03, therefore suggesting activity of T-DXd in brain mets.
Answer from: Medical Oncologist at Community Practice
Drug-antibody conjugates do have the ability to cross blood brain barrier and Trastuzumab-deruxtecan (T-DXd) has shown impressive intracranial activity across multiple studies.
A subgroup analysis of 24 patients with brain metastases in DESTINY-Breast 01, reported intracranial objective response of...
Comments
Medical Oncologist at Alabama Oncology
In a patient HER2-low disease with intracranial di...
In a patient HER2-low disease with intracranial di...